Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Study of CN128 in Thalassemia
NCT03673085Phase 1Completed
- Sponsor
- Hangzhou Zede Pharmaceutical Technology
- Start
- Jan 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Tiralos in thalassemia (16 arms), sponsored by Hangzhou Zede Pharmaceutical Technology. Primary endpoints: Maximum Tolerated Dose, Area Under the Curve from time 0 to t and 7 more. Started Jan 2018; status: completed.
02
Drugs
Tiralos
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT03673085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673085.